Inclusion of Montelukast in y-Cyclodextrin: Presenting a Mechanochemical Route to Improve Drug Stability and Solubility ^†

Abstract

Montelukast sodium (MLK) is a worldwide antiasthmatic drug. Commercial formulations still have some issues with solubility and instability to light and humidity. To overcome them, the present work reports inclusion compounds of MLK and γ-cyclodextrin (γ-CD). As a molecular capsule, CDs have the ability to protect the inclusion guest from degradation, enhance its solubility and alter the pharmacokinetic parameters. MLK⋅γ-CD inclusion compounds were prepared by mechanochemistry. Without using any solvent, γ-CD was pre-milled and then co-milled with an equimolar quantity of MLK in a ball mill at 600 cycles·min⁻¹. After 120 min of milling, the formation of MLK·γ-CD inclusion compounds was confirmed by powder X-ray diffraction and scanning electron microscopy. Additional studies, performed under pharmacopeia guidelines, showed that the prepared MLK⋅γ-CD inclusion compounds can indeed increase the dissolution of MLK when in ultrapure water or simulated intestinal fluid (without pancreatin). This way, the MLK⋅γ-CD inclusion compounds that are presented in this work are a promising solution for improving the therapeutic effectiveness of MLK.

1. Introduction

Montelukast sodium (MLK) is a widely used antiasthmatic agent [1,2,3,4,5] that can also be prescribed for other conditions, such as the treatment of allergic bronchopulmonary aspergillosis or chronic obstructive pulmonary disease (COPD) [6,7]. By blocking the cysteinyl-leukotriene 1 receptors, this active pharmaceutical ingredient (API) is able to significantly improve the lung function of these patients [1,8].

Nowadays, there are already three different dosage formulations of MLK on the market: tablets, chewable tablets and granules. Given this offer, the most suitable formulation can be chosen according to the patient’s needs concerning drug administration. For instance, MLK granule formulation is quite useful for administering to small babies and elderly patients, which could otherwise be a difficult challenge [9,10]. Nonetheless, and despite their proven efficiency, MLK formulations still present some limitations to their use, namely the poor solubility of the molecule in water (100–1000 mg/mL), as well as its instability to light, temperature, humidity and oxidation [9,11,12,13]. In an attempt to overcome these limitations, numerous approaches have been used, among them the use of cyclodextrins (CDs) as molecular carriers [9,12,14,15]. Cyclodextrins are a class of water-soluble cyclic oligosaccharides, well-known for the capacity to accommodate in their cavity a diversified class of guest molecules to form inclusion compounds (ICs). In the pharmaceutical industry, cyclodextrin inclusion com pounds are of particular interests because they can protect the included APIs from degradation and they can modify their physicochemical properties and pharmacokinetic parameters [16,17,18,19].

In this work, we report the inclusion compounds of MLK and gamma-cyclodextrin (γ-CD), which has been proven to have the ideal cavity size for the inclusion of this guest. Besides, and in contrast with the common procedures [12,20,21], γ-CD·MLK is herein prepared by mechanochemical grinding, without using any solvent. This method applied to MLK was first described by us in a previous study [22] and it is gaining growing interest in pharmaceutical and organic chemistry applications [23]. In the end, we expect that the preparation of γ-CD·MLK will modulate the physicochemical properties of MLK, in particular its solubility and stability. Upon preliminary results described in [22], in this study pharmacopeia guidelines will be used to determine the physicochemical properties of γ-CD·MLK when compared with the pure drug.

2. Experimental Section

2.1. Materials

γ-CD heptahydrate (MW = 1423.11), produced by Wacker Chemie (in Eddyville, Iowa, USA) with the commercial name Cavamax W8, was kindly donated by Ashland Industries Deutschland Gmbh (Düsseldorf, Germany). Montelukast sodium (>98% of purity, MW = 608.17), hereafter denominated MLK, was obtained from TCI or gently provided by Ashland (being produced by Ria International, Mumbai, India).

2.2. Equipment

Ball milling was carried out in a Philips MiniMill planetary apparatus, working at a velocity of 600 cycles min⁻¹. Samples were loaded into 50 mL calcium-doped zirconia grinding jars, each containing two yttrium-doped zirconia milling balls with 1 cm of diameter.

Laboratory Powder X-ray Diffraction (PXRD) data were collected at ambient temperature on an Empyrean PANalytical diffractometer, with working wavelengths of λ1 = 1.540598 Å and λ2 = 1.544426 Å (Cu Kα1,2 X radiation), equipped with an PIXcel 1D detector and a flat-plate sample holder in a Bragg-Brentano para-focusing optics configuration (45 kV, 40 mA). Intensity data were collected by the step-counting method (step 0.01°), in continuous mode, in the ca. 3.5 ≤ 2θ° ≤ 50° range.

Scanning Electron Microscopy (SEM) images were acquired with a Hitachi SU-70 Schottky emission instrument, working at 10 kV. Samples were prepared by deposition on aluminum sample holders followed by carbon coating in an Emitech K950X carbon evaporator. Energy-dispersive X-ray spectroscopy (EDS) mapping images were recorded using a Bruker QUANTAX 400 microanalysis system.

UV-Vis spectroscopy measurements for the studies of montelukast aqueous dissolution were conducted on a UV-2501 PC Shimadzu spectrometer, at a working wavelength of 346 nm.

2.3. Preparation of γ-CD·MLK by Mechanochemistry

γ-CD·MLK was prepared from a mixture containing amorphous γ-CD and MLK as received from the manufacturer, under the experimental conditions previously described by Barbosa et al. [22].

2.4. Dissolution of γ-CD·MLK versus Pure MLK: Preliminary In Vitro Studies

The assays on the dissolution rate of γ-CD·MLK and pure MLK, when in ultrapure water, were performed as previously described by Barbosa et al. [22].

2.5. Dissolution of γ-CD·MLK versus Pure MLK: According to Pharmacopeia Guidelines

The dissolution profile of γ-CD·MLK and pure MLK were analysed under (1) ultrapure water, (2) ultrapure water with 0.5% (m/v) of sodium dodecyl sulphate (SDS), (3) simulated intestinal fluid (without pancreatin), with pH buffered at 6.8, and (4) acetate buffer, pH 4.5; and according to Pharmacopeia guidelines. For this, a glass vessel with one liter capacity was filled with 900 mL of one of the aforementioned media. The vessel was immersed in a water bath of suitable dimensions, which allows for maintaining not only a temperature of 37 ± 0.5°, but also a constant and smooth flow of water during the tests. In addition to this, the medium inside the container was kept under continuous stirring with a rotor and a shaft with an agitation paddle attached to it.

10 mg of pure MLK, or an amount of γ-CD·MLK IC that corresponds to the same value of the pure drug, were added to the medium inside the container, which was then covered to delay medium evaporation. Aliquots were then collected at 5, 10, 20 and 30 min, for absorbance measurements under UV-Vis spectroscopy.

3. Results and Discussion

The preparation of γ-CD·MLK by co-milling reproduced previously described conditions [22]. In this work, we complement the previous work with details on the impact of inclusion on the physicochemical properties of MLK.

3.1. Preparation of IC through Mechanochemistry

Mechanochemical preparation of γ-CD·MLK followed the procedures described in Barbosa et al. [22]. The efficacy of this method is evaluated, on a first approach, by powder diffraction. As seen in Figure 1, upon 120 min of mechanical grinding an amorphous compound, with no reflections on its diffractogram, was obtained. This provides initial evidence of the formation of γ-CD·MLK because it is a typical feature for ICs prepared by mechanochemistry [24,25,26].

In addition, SEM images showed that in the physical mixture of MLK and amorphous γ-CD there are two distinct morphologies (Figure 2a). While MLK appears as an agglomerate of spheres, γ-CD particles present irregular shapes and sizes, with round edges. EDS mapping of this mixture further confirms the presence of the characteristic elements of MLK, namely S, Na and Cl, only in the agglomerates (Figure 2b). Upon 120 min of grinding, a uniform distribution of MLK was reached throughout the sample, confirming complete interaction between the two components (Figure 2d).

3.2. Dissolution of γ-CD·MLK IC in Pure Water

The dissolution profiles of both pure MLK and γ-CD·MLK were first studied in ultrapure water. In a previous study we had reported that till ca. 60 min, the IC showed a slightly higher dissolution than pure MLK [22]. Similarly, herein we noticed that over 30 min more dissolved from γ-CD·MLK (Figure 3).

Following these preliminary results, the dissolution profiles of pure MLK and γ-CD·MLK were evaluated under the guidelines of the US pharmacopea and the FDA for BCS class II drugs [27], i.e., in addition to the 30 min of analysis time, the apparatus, the volume of the medium, the drug dosage and the sampling times were adjusted as described in Section 2.5. Besides the recommended media (SDS 0.5%), pure water and aqueous buffers at pH values of 4.5 and 6.8 were also used.

In ultrapure water, MLK was practically unable to dissolve, both from pure MLK and from γ-CD·MLK. With pure MLK there was no trace of the drug dissolved in the medium; with γ-CD·MLK very low amounts of MLK were detected (Figure 4). In a way, these results are in accordance with those that we previously reported and showed that, at lower times, the dissolution profile of the pure drug versus the IC is similar, but the IC allows the dissolution of slightly higher amounts of MLK [22]. A completely different dissolution profile was seen with a solution of ultrapure water with 0.5% (m/v) of sodium dodecyl sulphate (SDS). In this medium, which is considered as a reference for dissolution studies of MLK, almost 100% of MLK dissolution was observed from both pure drug and γ-CD·MLK. Besides, the dissolution profiles were very similar, almost equivalent, for both the pure drug and γ-CD·MLK (Figure 5).

Additional studies were also made in media that simulate both the intestinal [28] and the duodenum environments. To mimic the intestinal environment, a solution of simulated intestinal fluid (without pancreatin), with pH buffered at 6.8 was used. In this medium the behavior of pure MLK and γ-CD·MLK was very similar to that previously observed in ultrapure water. While with pure MLK no drug was dissolved, with the IC a small amount of the drug was able to dissolve (Figure 6). In opposition to this, when in a medium of acetate buffer at pH 4.5, which mimics the duodenum environment, neither pure MLK nor γ-CD·MLK evidenced any dissolution, as no traces of MLK were detected in the medium (Figure 7). This may be due to the low pH (4.5), as MLK is a weak and hydrophobic acid that does not dissolve in an acidic media.

4. Conclusions

This work confirmed the reproducibility of the preparation of γ-CD·MLK by mechanochemistry [22] by advanced characterisation techniques, such as PXRD and SEM.

A thorough analysis of the dissolution profile of both pure MLK and γ-CD·MLK was performed. When in ultrapure water or in a medium that simulates the intestinal environment, the IC tended to afford a slightly higher dissolution of MLK (ca. 3–5%). Moreover, when in an SDS 0.5%(m/v) solution, the pharmacopoeia reference medium for the MLK dissolution test, the dissolution profiles of pure MLK and γ-CD·MLK IC were practically identical, thus indicating bioequivalence. Similar profiles for pure MLK and γ-CD·MLK were also seen in the simulated duodenum environment, with both compounds showing no dissolution of the MLK.

Overall, this work provides insightful results on the use of mechanochemistry as a sustainable methodology to form inclusion compounds between γ-CD and MLK. The prepared IC seems to be able to improve, at some extend, the dissolution of MLK in a few media, while having a dissolution profile equal to pure MLK in the reference medium and thus hinting at bioequivalence, a required trait for its incorporation into oral dosage forms. It is thus possible for γ-CD·MLK to help the pharmaceutical industry to overcome current setbacks and develop new MLK formulations with enhanced therapeutic effectiveness.